IPO registrations (S-1, F-1) · Registrants
Cardiff Oncology, Inc.
- SEC CIK
- 1213037 · filings on EDGAR ↗
- Former names
- Trovagene, Inc. (2013–2020); TrovaGene Inc. (2011–2013); XENOMICS INC (2004–2009); USED KAR PARTS INC (2003–2004)
- Registration
- Form S-1, first filed 2012-04-19, last 2020-07-06; 7 initial registrations, 12 amendments
- Outcome
- Final prospectus filed 2012-05-30; declared effective 2012-05-29; withdrawal requested 2017-10-31
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 11055 FLINTKOTE AVENUE, San Diego, CA 92121
- EIN
- 27-2004382
- Ticker
- CRDF (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Cardiff Oncology, Inc. on the corporate pages
Offering terms
- Final price
- $8.00 per share (424B4 filed 2012-05-30)
- Shares sold
- 1,150,000
- Gross proceeds
- $9,200,000 before underwriting discounts and any over-allotment option
- Listing
- OTC under the symbol TROV.PK
- Lead underwriters
- Aegis Capital
- Syndicate
- Summer Street Research Partners; Brean Murray, Carret & Co
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: TROVAGENE, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: CARDIFF ONCOLOGY, INC. EXACT (EIN (EXACT))
- Form D issuer: Cardiff Oncology, Inc. EXACT (CIK (EXACT))
- SEC filer: Cardiff Oncology, Inc. EXACT (CIK (EXACT))
- Person page: Abba David Poliakoff Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Rodney S Markin Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 39
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2012-04-19 | S-1 | S-1 (registration) | TrovaGene Inc. | 0001104659-12-026241 ↗ |
| 2012-05-09 | S-1/A | S-1/A (amendment) | TrovaGene Inc. | 0001104659-12-034698 ↗ |
| 2012-05-18 | S-1/A | S-1/A (amendment) | TrovaGene Inc. | 0001047469-12-006176 ↗ |
| 2012-05-22 | S-1/A | S-1/A (amendment) | TrovaGene Inc. | 0001047469-12-006223 ↗ |
| 2012-05-23 | S-1/A | S-1/A (amendment) | TrovaGene Inc. | 0001047469-12-006245 ↗ |
| 2012-05-25 | S-1/A | S-1/A (amendment) | TrovaGene Inc. | 0001047469-12-006333 ↗ |
| 2012-05-29 | EFFECT | EFFECT (declared effective) | TrovaGene Inc. | 9999999995-12-001662 ↗ |
| 2012-05-30 | 424B4 | 424B4 (final prospectus) | TrovaGene Inc. | 0001047469-12-006387 ↗ |
| 2013-02-04 | EFFECT | EFFECT (declared effective) | TrovaGene Inc. | 9999999995-13-000385 ↗ |
| 2013-02-12 | EFFECT | EFFECT (declared effective) | TrovaGene Inc. | 9999999995-13-000457 ↗ |
| 2015-11-30 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-15-003158 ↗ |
| 2016-06-13 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-16-004895 ↗ |
| 2017-10-25 | S-1 | S-1 (registration) | Trovagene, Inc. | 0001193125-17-319321 ↗ |
| 2017-10-31 | RW | RW (withdrawal request) | Trovagene, Inc. | 0001104659-17-064979 ↗ |
| 2017-11-17 | S-1/A | S-1/A (amendment) | Trovagene, Inc. | 0001193125-17-347062 ↗ |
| 2017-12-12 | S-1/A | S-1/A (amendment) | Trovagene, Inc. | 0001193125-17-367579 ↗ |
| 2017-12-14 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-17-003223 ↗ |
| 2017-12-15 | 424B4 | 424B4 (final prospectus) | Trovagene, Inc. | 0001193125-17-370880 ↗ |
| 2018-05-10 | S-1 | S-1 (registration) | Trovagene, Inc. | 0001193125-18-157775 ↗ |
| 2018-06-04 | S-1/A | S-1/A (amendment) | Trovagene, Inc. | 0001193125-18-183474 ↗ |
| 2018-06-05 | S-1/A | S-1/A (amendment) | Trovagene, Inc. | 0001193125-18-184599 ↗ |
| 2018-06-07 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-18-001442 ↗ |
| 2018-06-08 | S-1MEF | S-1MEF (added securities) | Trovagene, Inc. | 0001193125-18-187285 ↗ |
| 2018-06-11 | 424B4 | 424B4 (final prospectus) | Trovagene, Inc. | 0001193125-18-188623 ↗ |
| 2019-03-11 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-19-000414 ↗ |
| 2019-05-21 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-19-001160 ↗ |
| 2019-07-01 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-19-001490 ↗ |
| 2019-08-30 | S-1 | S-1 (registration) | Trovagene, Inc. | 0001104659-19-048262 ↗ |
| 2019-09-10 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-19-002057 ↗ |
| 2019-11-01 | S-1 | S-1 (registration) | Trovagene, Inc. | 0001104659-19-058988 ↗ |
| 2019-11-08 | S-1/A | S-1/A (amendment) | Trovagene, Inc. | 0001104659-19-061562 ↗ |
| 2019-11-12 | S-1/A | S-1/A (amendment) | Trovagene, Inc. | 0001104659-19-062057 ↗ |
| 2019-11-13 | EFFECT | EFFECT (declared effective) | Trovagene, Inc. | 9999999995-19-002565 ↗ |
| 2020-05-22 | S-1 | S-1 (registration) | Cardiff Oncology, Inc. | 0001628280-20-008292 ↗ |
| 2020-06-02 | EFFECT | EFFECT (declared effective) | Cardiff Oncology, Inc. | 9999999995-20-001317 ↗ |
| 2020-06-26 | S-1 | S-1 (registration) | Cardiff Oncology, Inc. | 0001628280-20-009971 ↗ |
| 2020-07-06 | S-1/A | S-1/A (amendment) | Cardiff Oncology, Inc. | 0001628280-20-010210 ↗ |
| 2020-07-10 | EFFECT | EFFECT (declared effective) | Cardiff Oncology, Inc. | 9999999995-20-001766 ↗ |
| 2022-04-25 | EFFECT | EFFECT (declared effective) | Cardiff Oncology, Inc. | 9999999995-22-001079 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2012-05-25 | S-1/A | registration statement | $1.00 | 1,666,667 | $1,666,667 | OTC TROV.PK | 3 | primary document; price sentence, shares headline, proceeds computed, cover names 3 | document ↗ | |
| 2012-05-30 | 424B4 | final prospectus | $8.00 | 1,150,000 | $9,200,000 | OTC TROV.PK | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Poliakoff Abba David | Director | 1 | 2008 | person page Fuzzy | |
| Sheinerman Kira | Director | 2 | 2008 | ||
| BRANCACCIO JOHN P | Director; Other | 23 | 2012–2022 | ||
| Tennant Stanley | Director | 22 | 2012–2018 | ||
| ADAMS THOMAS PHD | Director; Director,Officer; Other | Chief Executive Officer; Executive Chairman | 17 | 2012–2021 | |
| CERRONE GABRIEL | Director; Director,TenPercentOwner; Other | 9 | 2012–2013 | ||
| Hunter Robert Merrill | TenPercentOwner | 2 | 2012 | ||
| JACOB GARY S | Director; Other | 18 | 2012–2021 | ||
| SCHUH ANTONIUS | Director,Officer | CEO | 6 | 2012–2016 | |
| ZANIBONI STEVE | Director,Officer; Officer | CFO; Former CFO | 7 | 2012–2016 | |
| McGuigan Christopher | Director | 2 | 2013 | ||
| BRIDGER MANAGEMENT, LLC | Other; TenPercentOwner | 6 | 2013–2016 | ||
| MIGNONE ROBERTO | Other; TenPercentOwner | 6 | 2013–2016 | ||
| Billings Paul | Director | 12 | 2013–2018 | ||
| Markin Rodney S | Director | 23 | 2014–2026 | person page Fuzzy | |
| FELDBAUM CARL B | Director | 2 | 2015 | ||
| Erlander Mark | Director,Officer; Officer | Chief Executive Officer; Chief Scientific Officer | 32 | 2015–2025 | |
| Posard Matthew L. | Officer | Chief Commercial Officer | 2 | 2015–2016 | |
| WELCH WILLIAM J | Director,Officer; Officer | CEO; Chief Executive Officer | 9 | 2016–2018 | |
| Countouriotis Athena | Director | 3 | 2017–2019 | ||
| Armitage James O | Director | 12 | 2020–2026 | ||
| PACE GARY W | Director | 22 | 2020–2026 | ||
| White Lale | Director | 12 | 2020–2026 | ||
| Kelemen Vicki | Officer | Exec. VP and COO | 7 | 2020–2023 | |
| Kolchinsky Peter | TenPercentOwner | 1 | 2020 | ||
| RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | 1 | 2020 | ||
| Shah Rajeev M. | TenPercentOwner | 1 | 2020 | ||
| Mohindru Mani | Director; Director,Officer | Chief Executive Officer; Interim CEO | 10 | 2021–2026 | |
| TANNENBAUM RENEE P | Director | 9 | 2021–2026 | ||
| Levine James E. | Officer | Chief Financial Officer | 9 | 2021–2025 | |
| Ruffner Katherine L | Officer | Chief Medical Officer | 3 | 2021–2022 | |
| Smeal Tod | Officer | Chief Scientific Officer | 5 | 2022–2026 | |
| Kabbinavar Fairooz | Officer | Chief Medical Officer | 3 | 2023–2025 | |
| Sidhu Roger | Officer | Chief Medical Officer | 1 | 2025 | |
| Lindsay Brigitte Ute | Officer | Chief Accounting Officer | 2 | 2026 | |
| Muntner Joshua B | Officer | Chief Financial Officer | 3 | 2026 | |
| Aggarwal Ajay | Officer | Chief Operating Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-06-23 | Cardiff Oncology, Inc. | Biotechnology | $13,500,000 | $13,500,000 | 3 | 1 |
| 2020-06-01 | Cardiff Oncology, Inc. | Biotechnology | $2,500,000 | $2,500,000 | 1 | 1 |
| 2020-05-21 | Cardiff Oncology, Inc. | Biotechnology | $810,000 | $810,000 | 8 | 1 |
| 2020-04-14 | Trovagene, Inc. | Biotechnology | $2,084,000 | $2,084,000 | 1 | 1 |
| 2019-10-30 | Trovagene, Inc. | Biotechnology | $5,000,000 | $5,000,000 | 2 | 1 |
| 2019-08-28 | Trovagene, Inc. | Biotechnology | $1,500,000 | $1,500,000 | 1 | 1 |
| 2019-05-20 | Trovagene, Inc. | Biotechnology | $1,500,000 | $1,500,000 | 1 | 1 |
| 2019-04-10 | Trovagene, Inc. | Biotechnology | $1,500,000 | $1,500,000 | 1 | 1 |
| 2017-07-24 | Trovagene, Inc. | Biotechnology | $6,547,512 | $0 | 4 | 1 |
| 2012-03-26 | TrovaGene Inc. | Biotechnology | $6,598,200 | $6,598,200 | 40 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | TROVAGENE, INC. | CA | State business registries | EIN (EXACT, as the state registration reports it) |
| Form D issuer | Cardiff Oncology, Inc. | CA | Form D private offerings | CIK (EXACT) |
| Patent assignee | Cardiff Oncology, Inc. | CA | Patents (USPTO) | name and state |
| SEC filer | Cardiff Oncology, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | CARDIFF ONCOLOGY, INC. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | CARDIFF ONCOLOGY, INC. | EIN (EXACT) | ||
| Person page | Abba David Poliakoff | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Rodney S Markin | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), CA first:
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
- COLLATERAL THERAPEUTICS INC CA
- Life Technologies Corp CA
- DRUGABUSE SCIENCES INC CA
- STRATAGENE CORP CA
- Cordex Pharma, Inc. CA
- COTHERIX INC CA
- Eiger BioPharmaceuticals, Inc. CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health